Full title: Effects of maternal and paternal smoking on offspring cardiometabolic risk factors in adulthood: a multi-method intergenerational Mendelian randomization study

Short title: Parental smoking and adult offspring cardiometabolic risk

Authors: Grace M. Power[1,2,3]*¶, Tom A. Bond[1,2,3,4,5¶], Laxmi Bhatta[3,6], Bjørn Olav Åsvold[6,7,8], Ben Brumpton[6,7,9], Gibran Hemani[1,2], Deborah A. Lawlor[1,2], Geng Wang[3], Nicole Warrington[3,4], David M. Evans[1,3,4&], Gunn-Helen Moen[3,4,6,10&], George Davey Smith[1,2,11&]

* Corresponding author: Grace M. Power (grace.power@bristol.ac.uk).

¶ These authors contributed equally to this work (joint first authors).

& These authors also contributed equally to this work (joint senior authors).

Affiliations.

[1]*MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.*

[2]*Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.*

[3]*Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.*

[4]*Frazer Institute, University of Queensland, Woolloongabba, Australia.*

[5]*Department of Epidemiology and Biostatistics, Imperial College London, London, UK.*

[6]*HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Trondheim, Norway.*

[7]*HUNT Research Centre, Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Levanger, Norway.*

[8]*Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim 7030, Norway.*

[9]*Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.*

[10]*Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.*

[11] *NIHR Bristol Biomedical Research Centre Bristol, University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK.*

Abstract.

Parental smoking has been linked to several adverse offspring cardiometabolic outcomes; however, evidence is conflicting regarding the causal and long-term nature of these associations. We investigated the effects of maternal and paternal smoking, capturing exposure before, during, and after pregnancy, on eleven offspring cardiometabolic risk factors related to body composition, blood pressure, glucose, and lipid levels in adulthood. We applied a multi-method intergenerational Mendelian randomization (MR) framework, combining two-sample MR (outcome GWAS n = up to 564,160) and one-sample MR using genetic risk score (GRS) analyses (n = up to 17,484 genotyped mother, father, offspring trios with offspring cardiometabolic risk factors) from the Norwegian HUNT cohort and British UK Biobank and ALSPAC cohorts. Smoking behaviour was instrumented using genome-wide significant variants for smoking initiation and heaviness from large genome-wide association studies (2019 and 2022), with additional analyses of the *CHRNA5* variant rs16969968.

Using the two-sample MR approach, we found that an average change in adult offspring waist-hip-ratio (WHR) per one standard deviation (SD) increase in maternal cigarettes smoked per day of 0.25 SD (95% CI: 0.13, 0.38; 2019 GWAS), 0.19 SD (95% CI: 0.08, 0.31; 2022 GWAS) and 0.27 SD (95% CI: 0.07, 0.47; *CHRNA5* rs16969968). We also found tentative evidence of comparable effects on offspring body mass index and C-reactive protein. One-sample MR analyses using *CHRNA5* rs16969968, restricted to maternal ever-smokers, provided supporting evidence for a causal effect of maternal smoking heaviness on offspring WHR. We found little evidence that maternal smoking initiation affected WHR, and little evidence that maternal smoking heaviness affected the remaining cardiometabolic risk factors; paternal smoking showed no clear effect on any outcome. Results from sensitivity analyses were consistent with these main findings.

Our finding of higher central adiposity in adult offspring of mothers with a propensity to smoke more heavily provides further incentive for prospective mothers to quit or reduce smoking heaviness before, during, and after pregnancy. Triangulating these findings using alternative methods would be valuable.

Introduction.

Cardiovascular diseases (CVDs) are the most common cause of mortality worldwide (1). The Developmental Origins of Health and Disease (DOHaD) framework postulates that the development of adult cardiovascular disease is influenced by the environment in the preconception, fertilization, embryonic, fetal, and neonatal periods (2, 3). Environmental insults in early life are hypothesised to impede development, resulting in the permanent 'programming' of endocrine and metabolic function (4, 5), subsequently heightening susceptibility to cardiometabolic disease in adulthood (2, 6-9).

Smoking by mothers during pregnancy is a well-established modifiable risk factor for several adverse perinatal health outcomes (10, 11). Whilst attention has largely focused on the effects of maternal smoking on conception, pregnancy, fetal and child health, there have been concerns that perinatal exposure to smoking may play an important role in increased risk of cardiometabolic disorders in offspring in their later life (11, 12). Previous conventional epidemiological analyses have shown that parental smoking is associated with increased incidence of later life obesity and related comorbidities. For example, a meta-analysis comprising 19 multivariable regression studies (n=24,201 to 308,981) found that maternal prenatal smoking was associated with higher risks of overweight, obesity, and gestational diabetes mellitus in adult offspring, but not type 2 diabetes, hypertension, waist circumference, or total cholesterol (13). In addition, an individual patient data meta-analysis which included 26 studies of mother-child-pairs (n=238,340) indicated a positive linear dose-response relationship between the number of cigarettes smoked by mothers during pregnancy and offspring overweight in childhood and adolescence for up to 15 cigarettes per day (14). An association has also been identified between paternal smoking during preadolescence and increased BMI, fat mass, and waist circumference in male offspring, with no corresponding effect observed in female offspring (15). However, a larger study conducted in the Trøndelag Health Study (HUNT), designed to reproduce these earlier findings, found little evidence that exposure to parental smoke in preadolescence was associated with offspring BMI at a mean age of 29.1 years (16). Epigenetic studies have suggested that maternal and/or paternal smoking may affect DNA methylation in the offspring, including robust evidence for persistent methylation changes following maternal smoking in pregnancy, providing a plausible mechanism by which parental smoking could increase offspring obesity risk (17, 18).

The evidence for a causal effect of parental smoking on offspring cardiometabolic risk is contradictory. A proxy gene-by-environment Mendelian randomization (MR) study found little evidence for a causal effect of maternal smoking on 12 long-term offspring outcomes, including BMI and blood pressure, although the authors acknowledged a lack of power to detect such effects (19). In addition, studies employing a sibling comparison design, which contrasts siblings with discordant exposure to maternal smoking during pregnancy (with the aim of controlling for confounders that are shared by siblings), concluded that the observed associations between maternal smoking during pregnancy and offspring obesity were more likely to be confounded by shared familial characteristics than reflect a causal intrauterine mechanism (20, 21). Earlier paternal negative control studies suggested that maternal smoking in pregnancy showed larger associations with childhood overweight and obesity than paternal smoking in mutually adjusted models, which was interpreted as being more consistent with a causal intrauterine effect (22). This study design assumes that if a causal intrauterine effect of the maternal exposure on the offspring is present, the association of the maternal exposure with the outcome should be larger than the association of the equivalent paternal exposure (23). However, evidence from an individual participant data meta-analysis of 229,158 families shows that maternal and paternal smoking have similar associations with childhood overweight, a pattern more consistent with shared familial confounding than with a specific intrauterine effect (24).

Plausible explanations for the identification of an association between maternal or paternal smoking and cardiometabolic outcomes in adult offspring include: (i) consequences from noxious chemicals found in cigarette smoke impacting the oocyte or sperm, (ii) adverse intrauterine effects from associated chemical insults, (iii) postnatal exposure to parental smoking for the offspring, or (iv) potential confounding bias. In conventional epidemiological settings, biases induced by confounding pose challenges when inferring causality. Associations identified could be due to environmental confounding or to shared genetic effects (25).

Mendelian randomization (MR) is a technique that, provided specific assumptions are met, exploits the random distribution of genetic variants from parents to offspring, independent of the influence of other traits. This reduces susceptibility to confounding factors, including confounding by undiagnosed existing disease (reverse causation) (26, 27). Recent developments in intergenerational MR methodology (28) enable indirect estimation of the

117 effects of parental exposures on offspring adulthood outcomes by accounting for the direct
118 fetal genotype contribution (6).

119 We aimed to use intergenerational MR to test the hypothesis that maternal and paternal
120 smoking – before, during, or after pregnancy – cause a more adverse offspring cardiometabolic
121 risk factor profile in adulthood.

Methods.

This study adheres to the Strengthening The Reporting of Observational Studies in Epidemiology Using Mendelian Randomisation (STROBE-MR) guidelines *(29, 30)* (Supplementary Material 1).

Data sources and instruments

Inclusion criteria and participating cohorts

We analysed three large population-based prospective cohorts that had genome-wide SNP data available in mothers, fathers and offspring and cardiometabolic risk factors measured in adult offspring: the Trøndelag Health Study (HUNT), the UK Biobank (UKB), and the Avon Longitudinal Study of Parents and Children (ALSPAC). The selection of study participants for our main two-sample MR analysis is presented in Figure 1. Study participant selection for one-sample MR is presented in Figure S1.

HUNT. HUNT is a cohort study of the adult population in Trøndelag County, Norway, and comprises ~230,000 individuals aged ≥20 years (31, 32). Individuals were recruited in four surveys from 1984–2019, of which the HUNT2 and HUNT3 surveys were included in the present study. Invitee participation rates were 69% and 54%, respectively. Data on perinatal outcomes are available via linkage to the Medical Birth Registry of Norway (MBRN) (33) for individuals born after 1967. A total of 69,716 European ancestry offspring were available in HUNT, with genotype data available, of which 26,040 had maternal genotype data available and 19,784 had psaternal genotype data available (6, 34, 35). Parent-offspring pairs and trios were identified using kinship analysis implemented in the KING software package (36).

UKB. UKB is a cohort of 503,317 adult volunteers, recruited from across the UK aged 40–69 years between 2006 and 2010 (37). Parent-offspring pairs and trios were identified using kinship analysis implemented in the KING software package (36).

ALSPAC. ALSPAC is a birth cohort which enrolled 14,541 pregnant women living in Avon, England with expected dates of delivery between April 1, 1991, and December 31, 1992 (the estimated recruitment rate of those eligible was 80%) (38, 39). Further enrolments after 1998 resulted in a baseline sample of 14,901 children alive at one year of age. We used data

152 collected during pregnancy/birth and the 24-year follow up. Some study data were collected
153 and managed using Research Electronic Data Capture (REDCap) electronic data capture tools
154 hosted at the University of Bristol (40). Please note that the study website contains details of
155 all the data that is available through a fully searchable data dictionary and variable search tool:
156 http://www.bristol.ac.uk/alspac/researchers/our-data/. Parent-offspring pairs and trios were
157 identified by matching on study ID variables.

158 Informed consent was obtained from all participants and ethical approval was obtained from
159 the Regional Committee for Medical and Health Research Ethics, Central Norway (REK Central
160 application number 2018/2488) (HUNT), the North West Multi-centre Research Ethics
161 Committee (MREC) (ref 11/NW/0382) (UKB), and the ALSPAC Ethics and Law Committee and
162 the Local Research Ethics Committees (ALSPAC).

163 *Offspring cardiometabolic risk factors and birthweight*

164 Standard protocols were used to assess the eleven offspring cardiometabolic outcomes in
165 adulthood (body mass index (BMI), waist-hip-ratio (WHR), systolic (SBP) and diastolic (DBP)
166 blood pressure, blood glucose, glycated haemoglobin (HbA1c), total cholesterol, high density
167 lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides and
168 high sensitivity C-reactive protein (CRP)) (41, 42). For one-sample MR analyses, CRP was only
169 available in ALSPAC and UKB and HbA1c was only available in UKB. Blood pressure and lipid
170 measurements were corrected for antihypertensive and lipid lowering medication use as
171 described previously (41, 42). Briefly, blood pressure values for participants in HUNT and UKB
172 who reported taking antihypertensive medication were corrected by adding 15 mmHg and 10
173 mmHg to the raw SBP and DBP values respectively. Lipid values were corrected for participants
174 reporting taking lipid lowering medication in UKB by dividing the raw LDL cholesterol values by
175 0.7 and the raw total cholesterol and triglyceride values by 0.8 (41, 42). Biochemical values
176 were measured in fasting blood samples in ALSPAC and non-fasting in HUNT and UKB. Offspring
177 birthweight was employed as a positive control outcome in this analysis. A priori, we expected
178 to see a negative causal effect of smoking during pregnancy on birthweight (43-45).
179 Birthweight was extracted from the Medical Birth Registry of Norway (MBRN) in HUNT,
180 measured by trained research assistants or abstracted from the birth record/notification in
181 ALSPAC, and retrospectively self-reported at recruitment in UKB. CRP was strongly right
182 skewed, therefore was natural log transformed prior to GWAS.

183 *Genotyping, quality control and imputation in each cohort*

184 Genotyping, quality control and imputation in each cohort are described in detail in the
185 Supplementary Material 2 and elsewhere (34, 46-48). To summarise, participants were
186 genotyped using genome-wide arrays, followed by imputation of genome-wide variants. HUNT
187 participants were imputed using a customised Haplotype Reference Consortium (HRC) panel
188 including 2,201 Norwegian whole genome sequences. ALSPAC mothers and offspring were
189 imputed to the HRC panel (34, 47), and ALSPAC fathers to the 1000 Genomes phase 1 panel
190 (48). UKB participants were imputed to a merged HRC/UK10K panel (46). Imputed variants with
191 minor allele frequency (MAF) >1% and imputation accuracy score >0.8 were used for genome-
192 wide association study (GWAS) analyses.

193 *Parental smoking exposures*

194 We explored effects of maternal and paternal smoking initiation (by using genetic variants
195 associated with self-reported ever versus never smokers), intensity of smoking (by using
196 genetic variants associated with self-reported number of cigarettes per day the rs16969968
197 genetic variant in the *CHRNA5* gene shown to act primarily via smoking heaviness (49, 50)).
198 Thus, the measures we used aim to capture whether:

199 (i) current smoking compared to never smoking causes an effect on the outcomes of
200 interest, and
201 (ii) the intensity of smoking on the outcomes of interest suggests a dose-response
202 relationship.

203 This study utilised external genome-wide association studies (GWASs) carried out by the GWAS
204 and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) in 2019 and 2022 (Table S1)
205 (51, 52). We use both 2019 and 2022 GWAS. Larger GWAS typically identify variants with
206 smaller effect sizes, that may be more prone to pleiotropy if the primary phenotype is
207 imprecisely defined. Consequently, the smaller 2019 GWAS may yield estimates that are less
208 affected by pleiotropic bias. In addition, *CHRNA5* (which is a region containing the strongest
209 signal for smoking heaviness) (49, 50) was investigated using rs16969968 as a single
210 instrumental variable, sourced from the above 2022 GWAS of cigarettes per day (52). In
211 addition, there is weak association of this variant with never and ever smoking, thus allowing
212 stratification by these groups without introducing substantial collider bias (53). The GWAS

213 selected were conducted on participants of European ancestry to mitigate bias by population
214 stratification.

215 Statistical analysis

216 When genetic variants are used as instrumental variables in MR, the assumptions of
217 instrumental variables must be met, i.e., the genetic variants must (i) be strongly associated
218 with the exposure of interest and relevant to the population studied, here pregnant women
219 ("relevance"), (ii) not share common causes with the outcome ("independence"), and (iii) not
220 affect the outcome other than through the exposure ("exclusion-restriction") (54).

221 To block the path from parental genotype through offspring genotype to the offspring outcome
222 in an intergenerational context (which would be a violation of the "exclusion restriction"
223 assumption), MR is robust if (i) summary outcome associations are extracted from adjusted
224 GWAS (parental genotype adjusted for offspring genotype and if relevant, the other parent's
225 genotype) in a two-sample setting, or (ii) the association between maternal or paternal
226 unweighted GRS and offspring outcomes is adjusted for offspring genotype (and if relevant,
227 other parent GRS), in a one-sample setting (6, 28, 55, 56). There are other valid ways to conduct
228 intergenerational one-sample MR (e.g. maternal non-transmitted alleles) (57), which will not
229 be used in this current study.

230 *Summary level two-sample Mendelian randomisation*

231 For the main analysis, we conducted two-sample intergenerational MR using previously
232 derived GWAS summary statistics for each cardiometabolic risk factor (combined n for
233 maternal, paternal and offspring GWAS = up to 564,160), which employed maternal and
234 paternal genotype, and adjusted for the offspring's genotype (41, 42). These were generated
235 using a weighted linear modelling (WLM) approach, implemented in the DONUTS R package,
236 accounting for the correlation between the parental genotypes (58). The WLM estimated the
237 adjusted genetic effects (i.e. the mutually adjusted coefficients for maternal, paternal and
238 offspring genotype, fitted jointly in the same model) as linear combinations of the unadjusted
239 genetic effects (i.e. the coefficients for maternal, paternal and offspring genotype fitted in
240 separate, partially overlapping samples) (55, 59, 60). We use the shorthand "unadjusted" to
241 refer specifically to models that are unadjusted for parental/offspring genotype, as opposed to
242 the other covariates, inclufing offspring age, sex, and genetic principal components, which

were included in all models. We found that MR estimates changed very little when using genetic effects from a "duos" WLM (that only adjusted for offspring genotype) compared with estimates from a "trios" WLM (that adjusted for offspring genotype and the other parent's genotype). Since the duos WLM yields smaller standard errors, we present the duos results as our primary analysis (trios results are presented in the supplementary information). GWASs were carried out on all outcomes using mother, father, and offspring genotypes. We assume that imputation quality is the same across maternal, paternal and offspring GWAS. Methods are described in detail elsewhere (41, 42). In brief, offspring outcomes were regressed separately on maternal, paternal or offspring imputed genotype dosages, adjusting for offspring sex, age at outcome measurement (including linear, quadratic and sex interaction effects, for all outcomes except birthweight), technical covariates and the top 20 genetic principal components (calculated from maternal, paternal or offspring genotypes respectively) to adjust for population stratification. A linear mixed model using the fastGWA method (61) was used to account for cryptic relatedness. Parent-offspring pairs of European ancestry, for whom parental genotype and offspring phenotype data were available, were used. These analyses were conducted with HUNT, UKB, and ALSPAC cohorts independently and then meta-analysed using a fixed effects model implemented in METAL version 2011-03-25 (62). Standard quality control (QC) procedures were carried out including calculating the Linkage Disequilibrium Score Regression (LDSC) intercept and attenuation ratio.

To estimate the causal maternal (Figure 2A) and paternal (Figure 2B) effects of smoking initiation and intensity on offspring outcomes we first used two-sample intergenerational MR, with the SNP-exposure estimates from the GSCAN GWAS and the SNP-outcome estimates from the adjusted maternal/paternal/offspring GWAS. We computed the inverse variance weighted (IVW) estimate which takes a weighted mean of the variant-specific causal estimates using inverse variance weights (63). In IVW analyses, the regression slope (ratio) is forced through a zero intercept. This assumes balanced horizontal pleiotropy. We additionally ran sensitivity analyses using MR-Egger, weighted median, and weighted mode methods (64-66). MR-Egger evaluates the potential presence of pleiotropic effects by allowing for a non-zero intercept in the regression of the variant-outcome estimates on variant-exposure estimates (64). It provides an unbiased estimate of the causal effect even in the presence of horizontal pleiotropy assuming that the INstrument Strength Independent of Direct Effect (InSIDE) assumption holds (67). The weighted median method provides an alternative estimate of the

275 causal effect by considering the weighted median rather than the weighted mean of the
276 instrumental variable estimates (65). We checked for evidence of horizontal pleiotropy via
277 Cochran's Q test for heterogeneity, and by testing whether the MR Egger intercept differed
278 from zero. There is evidence that genetic variants associated with smoking also influence body
279 composition, suggesting potential shared genetic pathways between smoking behaviours and
280 adiposity (68, 69). Smoking-associated genetic variants are also correlated with socioeconomic
281 position, commonly indexed by educational attainment, indicating that these variants may
282 capture both behavioural and socioeconomic influences (52, 70, 71). To account for these
283 overlapping genetic relationships, we applied multivariable MR (MVMR) in our two-sample
284 analyses to estimate the effect of smoking initiation and smoking intensity on WHR, conditional
285 on educational attainment and BMI. By modelling these exposures jointly, MVMR provides
286 smoking-WHR estimates that account for these shared genetic pathways, under the
287 multivariable IV assumptions (72, 73). Instrument strength in the multivariable MVMR models
288 was evaluated using conditional F-statistics, which account for the inclusion of multiple,
289 potentially correlated exposures. These analyses were performed using the *TwoSampleMR* R
290 package (58).

291 Results subsequently underwent adjustment for multiple testing using Bonferroni correction
292 for 12 outcomes (corrected significance level p=0.004) to protect against Type 1 error (74).
293 Details of the input parameters are presented in Table S2.

294 *Individual-level one-sample MR using GRS analysis*

295 In one-sample MR, we explored effects of maternal and paternal intensity of smoking using
296 instruments identified in the GWAS described previously (51, 52). These one-sample analyses
297 represent reduced form associations, where offspring outcomes are regressed directly on
298 parental genetic scores without scaling by the genetic association with smoking exposure.
299 Accordingly, offspring outcomes were regressed separately on maternal, paternal, or offspring
300 genetic instruments, assuming an additive genetic model. Results therefore reflect the overall
301 genetic-outcome association, not the causal effect per unit change in the smoking exposure.
302 Unweighted genetic scores were constructed by summing smoking-raising alleles (Table S3).
303 We additionally ran these analyses using just the variant rs16969968 in *CHRNA5*. We examined
304 the association between the parental GRS of interest and offspring outcomes, adjusting for the
305 offspring's genetic score (and the other parent's GRS) calculated from the same smoking

306 heaviness-associated SNPs. These analyses were conducted in up to 17,484 mother-father-
307 offspring trios from HUNT, UKB and ALSPAC.

308 We constructed an unweighted GRS since regression coefficients obtained in the smoking
309 GWAS's might not accurately reflect effect sizes during pregnancy (75, 76). We fitted a linear
310 mixed model implemented in the GCTA software package (77) using a genetic relatedness
311 matrix (GRM) constructed from the offspring genotypes to account for relatedness and
312 population stratification. Known smoking-associated SNPs and any SNPs within ±1 Mb of these
313 loci (to account for linkage disequilibrium) were excluded from GRM construction (6). SNPs
314 included in GRSs were selected from GWAS meta-analyses as genome-wide significant ($P < 5 \times$
315 10^{-8}) and conditionally independent, based on LD clumping or fine-mapping procedures
316 described by the original studies (51, 52). All analyses were adjusted for offspring age at
317 measurement and sex. The GRM mitigated the need to adjust for PCs. Parent-offspring pairs
318 of European ancestry, for whom parental genotype and offspring phenotype data were
319 available, were used. We implemented a complete-case approach, excluding individuals with
320 missing values from the analysis. These analyses were conducted in HUNT, UKB and ALSPAC
321 and then meta-analysed. A fixed-effects meta-analysis of regression coefficients from the three
322 cohorts was conducted using Stata version 16 (78).

323 *Stratified analysis*

324 If our genetic instruments for smoking heaviness (including rs16969968 in the *CHRNA5* gene)
325 are valid, we would expect these variants to only indicate a causal effect when the
326 mother/father is a smoker. If a causal effect is detected in parental never-smokers, this implies
327 that the *CHRNA5* gene is influencing the offspring outcome via mechanisms other than
328 smoking heaviness (i.e. horizontal pleiotropy). We therefore repeated the *CHRNA5* gene MR
329 analyses, stratifying the sample to parental ever-smokers and never-smokers (49). For two
330 sample analyses we only had a sufficiently large sample to run stratified analyses for
331 birthweight (because the WLM relies on LD score regression (79), which has stringent sample
332 size requirements), whereas we ran stratified one-sample analysis for adult outcomes too.

333 Results.

334 *Summary level two-sample Mendelian randomisation*

335 The GWAS meta-analyses used for the SNP-outcome association in the two-sample MR
336 included between 14,481 (for HbA1c with paternal genotype) and 511,253 (for DBP with
337 offspring genotype) participants (Table S4) (80, 81).

338 We found strong evidence of an average change in adult offspring WHR per one standard
339 deviation (SD) increase in maternal cigarettes smoked per day of 0.25 SD (95% CI: 0.13, 0.38)
340 using GWAS carried out in 2019, 0.19 SD (95% CI: 0.08, 0.31) using the GWAS carried out in
341 2022, and 0.27 SD (95% CI: 0.07, 0.47) using *CHRNA5* rs16969968 (Figure 3A, Table S5). The
342 estimates presented here all derive from unstratified analyses; stratified analyses are
343 presented later. There was weaker evidence that increased maternal smoking heaviness had a
344 causal effect on higher BMI (average change in SD of BMI in adult offspring per maternal
345 cigarettes smoked per day of 0.23 SD (95% CI: 0.07, 0.39) using GWAS carried out in 2019, 0.14
346 SD (95% CI: 0.00, 0.29) using GWAS carried out in 2022 and 0.11 SD (95% CI: -0.13, 0.35) using
347 *CHRNA5* rs16969968) and CRP (average change in SD of CRP in adult offspring 1SD greater
348 maternal cigarettes smoked per day of 0.24 SD (95% CI: 0.08, 0.40) using GWAS carried out in
349 2019, 0.20 SD (95% CI: 0.04, 0.36) using GWAS carried out in 2022, and 0.25 SD (95% CI: 0.01,
350 0.49) using *CHRNA5* rs16969968). Corresponding paternal effect estimates are presented in
351 Table S6. In the analyses using the trios WLM for the outcome GWAS (in which the parental
352 genetic effects were adjusted for the other parent's genotype as well as the offspring's
353 genotype), results were similar, although the confidence intervals were wider due to the lower
354 statistical power of the trios WLM versus the duos WLM (Figure S2).

355 Point estimates from the two-sample weighted median, weighted mode and MR-Egger
356 methods were similar to IVW estimates and evidence remained robust for the maternal effect
357 for smoking heaviness on offspring WHR in later life (Table S5). In addition, Cochran's Q test
358 provided little evidence for between-SNP heterogeneity, and there was not strong evidence
359 that the MR Egger intercept differed from zero (Table S7). This suggests little evidence that
360 horizontal pleiotropy is driving these results. After correcting for multiple testing using a
361 Bonferroni test, evidence of an effect remained for maternal smoking heaviness on increased
362 WHR and BMI only (using p=0.004). Findings for adult offspring outcomes using the unadjusted

363 GWAS sensitivity analyses are presented in Table S8 for maternal exposures and Table S9 for
364 paternal exposures. MVMR analyses indicated that there remained strong evidence for the
365 effect of maternal smoking heaviness on WHR in offspring in later life after accounting for BMI
366 as well as educational attainment (Table S10). There was little evidence of an effect of either
367 educational attainment or BMI on WHR in offspring after adjustment for any maternal smoking
368 indicator. Comparison of the conditional F-statistics showed that the instruments for BMI and
369 educational attainment were substantially stronger than those for the smoking exposures
370 (Table S10). The strength of the BMI and educational attainment instruments was largely
371 preserved when conditioned on smoking, indicating that these estimates were not affected by
372 SNP non-overlap. In contrast, conditioning led to considerable weakening of the smoking
373 instruments, consistent with the shared genetic architecture between smoking behaviour and
374 BMI. Accordingly, estimates for smoking heaviness should be interpreted with some caution;
375 however, the persistence of an association with offspring WHR after adjustment for BMI
376 suggests that this effect is not solely attributable to shared genetic pathways and may in fact
377 be attenuated by weak-instrument bias.

378 *Individual-level one-sample MR using GRS analysis*

379 The individual-level one-sample GRS analysis comprised between 16,942 and 17,484 mother-
380 father-offspring trios (Table 1 and Table S11). These one-sample analyses represent reduced
381 form associations between parental genetic scores and offspring outcomes. One-sample MR
382 in the total population indicated that higher genetically predicted maternal smoking heaviness
383 (using rs16969968 in the *CHRNA5* SNP) had a positive effect on WHR, TC, and LDL-cholesterol
384 in offspring in later life (Figure 4A, Table S12). There was no evidence of paternal smoking
385 effects (Figure 4B, Table S13). Cohort-specific results are presented in Tables S14-S16. Effect
386 estimates obtained using the unweighted smoking GRS were smaller than those from
387 rs16969968 in *CHRNA5*, consistent with differences in instrument scale: a single *CHRNA5* allele
388 has a larger established effect on smoking intensity than a one-allele change in the unweighted
389 multi-locus score. Consequently, the unweighted GRS yields more diluted reduced-form
390 associations.

391 *Stratified analysis*

392 For GWAS of birthweight stratified by parental smoking status, analysis comprised between
393 10,719 and 136,933 participants in maternal ever smokers, 8,094 and 104,002 participants in
394 maternal never smokers, 9,425 and 27,726 participants in paternal ever smokers and 5,367
395 and 18,718 participants in paternal never smokers (Table S17). In analyses employing the
396 unadjusted GWAS (i.e. using genetic effects that were not adjusted for the offspring's or other
397 parent's genotype), in the unstratified sample (including parental never and ever smokers) we
398 found suggestive evidence that maternal and paternal smoking initiation caused lower
399 birthweight (Figure 5, Table S18). We also found some weak evidence that greater maternal
400 smoking heaviness caused lower offspring birth weight. However, in the maternal ever smoker
401 group these effects were noticeably stronger. Interestingly, in the maternal never smoker
402 group the effects of maternal smoking heaviness flipped sign and became weakly positive.
403 Taken together, these observations support our use of birth weight as a positive control
404 outcome. In the analyses using the adjusted GWAS, the direction of effect was often consistent
405 with analyses using the unadjusted GWAS, but the adjusted GWAS had lower statistical power,
406 resulting in weaker evidence (Figure S3, Figure S4). There was little evidence that paternal
407 smoking heaviness influenced offspring birth weight (Figure 5, Figure S3; Table S18).

408 The one-sample MR stratified smoking samples comprised between 8,814 and 9,065
409 participants in maternal ever smokers, 7,357 and 7,624 in maternal never smokers, 12,004 and
410 12,339 in paternal ever smokers and 4,445 and 4,623 in paternal never smokers, with numbers
411 differing across outcomes (Table S11). Whilst the sample size was smaller and thus power was
412 low, the magnitude of effect became slightly stronger in ever smokers for the effects of
413 maternal smoking heaviness instrumented by rs16969968 in *CHRNA5* on WHR and maternal
414 smoking heaviness instrumented by cigarettes per day on BMI (Figure 6A, Table S12). There
415 was additionally some evidence of an effect of maternal smoking heaviness instrumented by
416 rs16969968 in *CHRNA5* on DBP and SBP in ever smokers. There was weak evidence of an effect
417 of maternal smoking heaviness instrumented by rs16969968 in *CHRNA5* on TC and LDL-
418 cholesterol in never smokers, although this could have been attributable to type 1 error (Figure
419 6B, Table S12). There was very little evidence of paternal smoking effects on any outcome
420 (Table S13). As with all stratified analyses, the potential for collider bias should be considered
421 when interpreting these results.

Discussion.

Employing intergenerational MR analyses across three large cohorts, we found robust evidence supporting a causal effect of greater maternal smoking heaviness (but not initiation) on higher WHR in adult offspring. We also found suggestive evidence that greater maternal smoking heaviness causes greater offspring adult BMI and circulating CRP. We did not find robust evidence of maternal smoking effects on other cardiometabolic risk factors or of paternal smoking effects on any of the outcomes investigated. The MR models in this study cannot distinguish whether the estimated effects reflect maternal or paternal smoking before conception, during pregnancy, or after birth. They are therefore not specific to exposure in pregnancy, and we cannot determine from these results whether the observed effect of maternal smoking on adult offspring WHR is driven by pre-conception, intrauterine or postnatal mechanisms. A purely postnatal explanation appears less likely based on the weaker paternal effects observed, although this should be interpreted with caution, as unmeasured differences in parental caregiving, contact, or social expectations may contribute to stronger mother-offspring effects. Thus, our findings may reflect true effects that are similar across exposure to maternal smoking at different life stages, or alternatively we may have missed effects that are stronger or weaker at different critical or sensitive periods. If the assumptions underpinning our analyses hold, this study is consistent with previous non-genetic epidemiological findings, which identify an association between maternal smoking and higher central adiposity in offspring, that persists into adulthood (13, 14). Although there was some indication of an effect of maternal smoking on BMI and circulating CRP in the two-sample analyses, the BMI effect was weaker than that observed for WHR and did not replicate in the one-sample MR. CRP was not available for one-sample analysis. Overall, this pattern may suggest that any influence of maternal smoking heaviness relates specifically to the fat mass component of BMI.

Several potential mechanisms for the effect of maternal smoking on offspring adiposity have been proposed. In animal studies, maternal nicotine exposure has been associated with alterations in adipose tissue and glucose metabolism (82, 83). Although reduced fetal growth has been suggested as a DOHaD-related mechanism (84, 85), evidence from MR studies provides limited support for broad intrauterine programming effects (57), and such interpretations should therefore be made cautiously. Observational studies also show that

453 associations between parental smoking and offspring overweight are often independent of
454 fetal or postnatal growth and birth weight, which further limits support for a fetal growth–
455 mediated explanation (12). Furthermore, sibling studies have reported that the association
456 between parental smoking and offspring obesity/overweight in childhood and adulthood
457 attenuates when assessed within siblings (20, 21). Such attenuation could indicate that familial
458 confounding is an important driver of these associations, although the sibling estimates
459 typically have wide confidence intervals which would also be consistent with meaningful causal
460 effects. It is also difficult to directly compare effect sizes from our MR analyses with those from
461 previous sibling studies, due to differences in the definition and measurement units of the
462 smoking exposures and in estimands obtained across methods.

463 The limited evidence we observed for an effect of paternal smoking on WHR in adult offspring
464 may be considered in the context of previous maternal and paternal comparison studies (22,
465 86). Such studies are often interpreted under the assumption that, if an intrauterine effect
466 exists, the association of maternal smoking with offspring outcomes should be stronger than
467 the equivalent paternal association (87). Earlier observational investigations and meta-
468 analyses appeared consistent with this assumption, reporting more adverse maternal relative
469 to paternal associations of parental smoking with childhood overweight and obesity (22, 86,
470 88). However, maternal-paternal comparisons are generally more informative for pregnancy
471 outcomes, which occur during the exposure window itself, than for long-term offspring
472 outcomes (23), where postnatal environmental and familial influences can accumulate and
473 obscure intrauterine effects. Consistent with this, a more recent individual participant data
474 meta-analysis including 229,158 families (24) reported maternal and paternal associations of
475 comparable magnitude for childhood overweight, indicating that earlier maternal-paternal
476 differences may have reflected residual confounding rather than true intrauterine effects.
477 These limitations underscore the value of approaches such as MR in differentiating putative
478 intrauterine causal effects from shared familial confounding when interrogating long-term
479 offspring phenotypes.

480 Single-trait assortative mating, or nonrandom matching between spouses, occurs when
481 partners are selected on the basis of a single phenotype (89). For instance, if individuals who
482 smoke are more likely to select partners who also smoke, the resulting enrichment of smoking-
483 concordant couples could bias associations in our study. In using a WLM to estimate parental

484 genetic effects, we assume that the same phenotype was measured in the samples of mothers,
485 fathers, and offspring, and that cross-locus genetic correlations due to assortative mating are
486 absent. In addition, within a family context, it is difficult to fully unpick the effects of individual
487 behaviour. Whilst it has been shown that the DNA methylation signature associated with
488 passive smoke exposure is much less pronounced than that of own smoking, passive smoking
489 or offspring's own smoking behaviour may still have an impact on findings. Therefore, the
490 effects that we found may encompass (i) maternal exposure to second-hand smoke from the
491 partner during pregnancy, due to unmodelled assortative mating effects, (ii) postnatal
492 exposure to second-hand smoke during the offspring's childhood, and (iii) offspring smoking in
493 adolescence and early adulthood.

494 There are several strengths of this study. For the main analysis, we took advantage of novel
495 statistical methods (28, 60, 90, 91) recently developed to conduct intergenerational two-
496 sample MR, by estimating the effects of parental genotype on offspring outcomes in
497 adulthood, adjusting for the offspring's own genotype and (when necessary) the other parent's
498 genotype. This approach removed the need to analyse a subset of individuals with complete
499 maternal, paternal, and offspring genotype data available (as we have done for the one-sample
500 MR analyses). In addition, we applied linear mixed model association methods to data from
501 large population-based cohorts that comprised related individuals: HUNT, UKB and ALSPAC,
502 increasing our available sample size considerably. We adjusted for the offspring's and other
503 parent's genotype, which is crucial to preserve the key exclusion restriction assumption of MR
504 (92). Importantly, we included birth weight as a positive control outcome, demonstrating that
505 our method is able to detect the expected causal effect of maternal smoking on offspring birth
506 weight. In particular, our MR results indicated an effect of both maternal and paternal smoking
507 initiation on offspring birth weight. However, the presence of a paternal effect raises the
508 possibility that the smoking initiation instrument may be picking up effects of other exposures
509 besides smoking, via horizontal pleiotropy. We were also able to stratify MR analyses by
510 parental smoking status; if parental smoking heaviness exhibits a putative causal effect in
511 parental never smokers, this indicates our method is biased. We found some evidence that
512 heavier maternal smoking causes lower offspring birth weight in the unstratified sample, but
513 these effects were stronger in ever smokers.

514 An important limitation of this study is that despite relatively large sample sizes, low power
515 was an issue, particularly within some of the stratified sensitivity analyses. These analyses
516 should therefore be interpreted with appropriate caution. Moreover, smoking initiation is an
517 example of a complex behavioural exposure where pleiotropy may be operating (93, 94).
518 Smoking initiation has been shown to associate with risk-taking behaviours, personality traits,
519 and externalising disorders (70, 71). To strengthen this study, we explored several indicators
520 for smoking and conducted multiple sensitivity analyses. The relationship between smoking
521 and body composition is particularly complex (68, 69). Suggestions of a common biological
522 basis for nicotine addiction and obesity have been proposed, with higher adiposity influencing
523 smoking behaviour (69, 95). This link identified between obesity and smoking behaviour may
524 have implications for weight control and smoking prevention strategies (69). We identified
525 several body composition measures which exhibit high genetic correlation with smoking
526 indicators in publicly available GWAS data (52). Our MVMR analyses suggest that smoking
527 initiation may be an unreliable exposure for MR analyses. In addition, a potential source of bias
528 could arise from gene-sex interactions in the two-sample WLM analyses, if residual sex
529 differences in SNP-outcome effects remain even after adjusting for offspring sex. This
530 consideration is particularly relevant for WHR, which has well-established sex-specific genetic
531 architecture (96), and in theory this could contribute to the stronger maternal MR estimate
532 observed for this trait. However, since we observed similar maternal effects on BMI and CRP,
533 which are less sexually dimorphic genetically, this is unlikely to be a major source of bias for
534 our MR analyses. While all our outcome GWAS adjusted for offspring sex, they did not explicitly
535 model gene-sex interactions, so some residual bias cannot be ruled out. Despite this, previously
536 findings suggest that maternal and paternal BMI and glucose traits both exhibit null MR effects
537 on offspring cardiometabolic risk factors in this data set (41, 42). Such bias is therefore unlikely
538 to fully explain these patterns of associations. Finally, our study included only participants of
539 White European ancestry from high income countries, therefore our results may not be
540 generalisable to other populations.

541 In conclusion, our study provides evidence that heavier maternal smoking causes greater WHR
542 in adult offspring, with more tentative indications of effects on offspring BMI and circulating
543 CRP. We did not find robust evidence for maternal smoking effects on other cardiometabolic
544 risk factors, or for effects of paternal smoking on any of the cardiometabolic factors examined.

545 Triangulation with complementary study designs will be important for strengthening causal
546 inference, and our findings, which are compatible with causal effects of maternal smoking on
547 central adiposity in adult offspring, reinforce the public-health rationale for promoting smoking
548 cessation prior to pregnancy.

Acknowledgements.

The Trøndelag Health Study (HUNT) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology NTNU), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. In addition, we are extremely grateful to all the families who took part in the ALSPAC study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. We would like to thank the UK Biobank study and all participants who contributed to it, as well as the authors of the GWAS who made their summary statistics available for the benefit of this work.

References.

1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204-22.
2. Barker DJP, Hales CN, Fall CHD, Osmond C, Phipps K, Clark PMS. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36(1):62-7.
3. Langley-Evans SC, McMullen S. Developmental Origins of Adult Disease. Medical Principles and Practice. 2010;19(2):87-98.
4. Deodati A, Inzaghi E, Cianfarani S. Epigenetics and In Utero Acquired Predisposition to Metabolic Disease. Frontiers in Genetics. 2020;10.
5. Mandy M, Nyirenda M. Developmental Origins of Health and Disease: the relevance to developing nations. Int Health. 2018;10(2):66-70.
6. Moen G-H, Brumpton B, Willer C, Åsvold BO, Birkeland KI, Wang G, et al. Mendelian randomization study of maternal influences on birthweight and future cardiometabolic risk in the HUNT cohort. Nature Communications. 2020;11(1):5404.
7. Barker DJP, Osmond C. INFANT MORTALITY, CHILDHOOD NUTRITION, AND ISCHAEMIC HEART DISEASE IN ENGLAND AND WALES. The Lancet. 1986;327(8489):1077-81.
8. Barker DJP, Osmond C, Winter PD, Margetts B, Simmonds SJ. WEIGHT IN INFANCY AND DEATH FROM ISCHAEMIC HEART DISEASE. The Lancet. 1989;334(8663):577-80.
9. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008;359(1):61-73.
10. Mund M, Louwen F, Klingelhoefer D, Gerber A. Smoking and pregnancy--a review on the first major environmental risk factor of the unborn. Int J Environ Res Public Health. 2013;10(12):6485-99.
11. Banderali G, Martelli A, Landi M, Moretti F, Betti F, Radaelli G, et al. Short and long term health effects of parental tobacco smoking during pregnancy and lactation: a descriptive review. Journal of Translational Medicine. 2015;13(1):327.
12. Oken E, Levitan EB, Gillman MW. Maternal smoking during pregnancy and child overweight: systematic review and meta-analysis. International Journal of Obesity. 2008;32(2):201-10.
13. Kataria Y, Gaewsky L, Ellervik C. Prenatal smoking exposure and cardio-metabolic risk factors in adulthood: a general population study and a meta-analysis. International Journal of Obesity. 2019;43(4):763-73.
14. Albers L, Sobotzki C, Kuß O, Ajslev T, Batista RFL, Bettiol H, et al. Maternal smoking during pregnancy and offspring overweight: is there a dose–response relationship? An individual patient data meta-analysis. International Journal of Obesity. 2018;42(7):1249-64.
15. Northstone K, Golding J, Davey Smith G, Miller LL, Pembrey M. Prepubertal start of father’s smoking and increased body fat in his sons: further characterisation of paternal transgenerational responses. European Journal of Human Genetics. 2014;22(12):1382-6.
16. Carslake D, Pinger PR, Romundstad P, Davey Smith G. Early-Onset Paternal Smoking and Offspring Adiposity: Further Investigation of a Potential Intergenerational Effect Using the HUNT Study. PLoS One. 2016;11(12):e0166952.
17. Kitaba NT, Knudsen GTM, Johannessen A, Rezwan FI, Malinovschi A, Oudin A, et al. Fathers' preconception smoking and offspring DNA methylation. Clin Epigenetics. 2023;15(1):131.

18. Richmond RC, Suderman M, Langdon R, Relton CL, Davey Smith G. DNA methylation as a marker for prenatal smoke exposure in adults. Int J Epidemiol. 2018;47(4):1120-30.
19. Yang Q, Millard LAC, Davey Smith G. Proxy gene-by-environment Mendelian randomization study confirms a causal effect of maternal smoking on offspring birthweight, but little evidence of long-term influences on offspring health. Int J Epidemiol. 2020;49(4):1207-18.
20. Iliadou AN, Koupil I, Villamor E, Altman D, Hultman C, Långström N, et al. Familial factors confound the association between maternal smoking during pregnancy and young adult offspring overweight. International Journal of Epidemiology. 2010;39(5):1193-202.
21. Hawkins SS, Baum CF, Rifas-Shiman SL, Oken E, Taveras EM. Examining Associations between Perinatal and Postnatal Risk Factors for Childhood Obesity Using Sibling Comparisons. Childhood Obesity. 2019;15(4):254-61.
22. Riedel C, Schönberger K, Yang S, Koshy G, Chen Y-C, Gopinath B, et al. Parental smoking and childhood obesity: higher effect estimates for maternal smoking in pregnancy compared with paternal smoking—a meta-analysis. International Journal of Epidemiology. 2014;43(5):1593-606.
23. Davey Smith G. Assessing intrauterine influences on offspring health outcomes: can epidemiological studies yield robust findings? Basic Clin Pharmacol Toxicol. 2008;102(2):245-56.
24. Philips EM, Santos S, Trasande L, Aurrekoetxea JJ, Barros H, von Berg A, et al. Changes in parental smoking during pregnancy and risks of adverse birth outcomes and childhood overweight in Europe and North America: An individual participant data meta-analysis of 229,000 singleton births. PLOS Medicine. 2020;17(8):e1003182.
25. Horikoshi M, Beaumont RN, Day FR, Warrington NM, Kooijman MN, Fernandez-Tajes J, et al. Genome-wide associations for birth weight and correlations with adult disease. Nature. 2016;538(7624):248-52.
26. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22.
27. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133-63.
28. Evans DM, Moen G-H, Hwang L-D, Lawlor DA, Warrington NM. Elucidating the role of maternal environmental exposures on offspring health and disease using two-sample Mendelian randomization. International Journal of Epidemiology. 2019;48(3):861-75.
29. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-21.
30. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ. 2021;375:n2233.
31. Åsvold BO, Langhammer A, Rehn TA, Kjelvik G, Grøntvedt TV, Sørgjerd EP, et al. Cohort Profile Update: The HUNT Study, Norway. International Journal of Epidemiology. 2022;52(1):e80-e91.
32. Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, et al. Cohort Profile: the HUNT Study, Norway. Int J Epidemiol. 2013;42(4):968-77.

652 33. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and
653 surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;79(6):435-9.
654 34. Brumpton BM, Graham S, Surakka I, Skogholt AH, Løset M, Fritsche LG, et al. The
655 HUNT study: A population-based cohort for genetic research. Cell Genomics.
656 2022;2(10):100193.
657 35. Næss M, Kvaløy K, Sørgjerd EP, Sætermo KS, Norøy L, Røstad AH, et al. Data Resource
658 Profile: The HUNT Biobank. Int J Epidemiol. 2024;53(3).
659 36. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust
660 relationship inference in genome-wide association studies. Bioinformatics. 2010;26(22):2867-
661 73.
662 37. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open
663 access resource for identifying the causes of a wide range of complex diseases of middle and
664 old age. PLoS Med. 2015;12(3):e1001779.
665 38. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, et al. Cohort
666 Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J
667 Epidemiol. 2013;42(1):97-110.
668 39. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al. Cohort Profile:
669 the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and
670 Children. Int J Epidemiol. 2013;42(1):111-27.
671 40. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
672 capture (REDCap)--a metadata-driven methodology and workflow process for providing
673 translational research informatics support. J Biomed Inform. 2009;42(2):377-81.
674 41. Bond TA, Bhatta L, Yang Q, Moen G-H, Wang G, Beamont RN, et al. Parental body
675 mass index and offspring cardiovascular risk factors in adulthood: an intergenerational
676 Mendelian randomization study. medRxiv. 2025:2025.05.06.25327111.
677 42. Bhatta L, Bond TA, Warrington NM, Wang G, Denos M, Evans DM, et al. Exploring the
678 effect of maternal glycemic traits on offspring cardiometabolic risk factors in adulthood: an
679 intergenerational Mendelian randomization study. medRxiv. 2025:2025.05.07.25326949.
680 43. Pereira RD, Rietveld CA, van Kippersluis H. The interplay between maternal smoking
681 and genes in offspring birth weight. Journal of Human Resources. 2022.
682 44. Tyrrell J, Huikari V, Christie JT, Cavadino A, Bakker R, Brion M-JA, et al. Genetic
683 variation in the 15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5–CHRNA3–
684 CHRNB4) interacts with maternal self-reported smoking status during pregnancy to influence
685 birth weight. Human molecular genetics. 2012;21(24):5344-58.
686 45. Wang X, Zuckerman B, Pearson C, Kaufman G, Chen C, Wang G, et al. Maternal
687 cigarette smoking, metabolic gene polymorphism, and infant birth weight. Jama.
688 2002;287(2):195-202.
689 46. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
690 resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-9.
691 47. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A
692 reference panel of 64,976 haplotypes for genotype imputation. Nature Genetics.
693 2016;48(10):1279-83.
694 48. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An
695 integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-
696 65.

697 49. Lassi G, Taylor AE, Timpson NJ, Kenny PJ, Mather RJ, Eisen T, et al. The CHRNA5-A3-B4
698 Gene Cluster and Smoking: From Discovery to Therapeutics. Trends Neurosci.
699 2016;39(12):851-61.
700 50. Wang JC, Cruchaga C, Saccone NL, Bertelsen S, Liu P, Budde JP, et al. Risk for nicotine
701 dependence and lung cancer is conferred by mRNA expression levels and amino acid change
702 in CHRNA5. Human Molecular Genetics. 2009;18(16):3125-35.
703 51. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2
704 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat
705 Genet. 2019;51(2):237-44.
706 52. Saunders GRB, Wang X, Chen F, Jang S-K, Liu M, Wang C, et al. Genetic diversity fuels
707 gene discovery for tobacco and alcohol use. Nature. 2022;612(7941):720-4.
708 53. Millard LAC, Munafò MR, Tilling K, Wootton RE, Davey Smith G. MR-pheWAS with
709 stratification and interaction: Searching for the causal effects of smoking heaviness identified
710 an effect on facial aging. PLOS Genetics. 2019;15(10):e1008353.
711 54. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. Cold
712 Spring Harb Perspect Med. 2022;12(1).
713 55. Warrington NM, Beaumont RN, Horikoshi M, Day FR, Helgeland Ø, Laurin C, et al.
714 Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic
715 risk factors. Nature Genetics. 2019;51(5):804-14.
716 56. Warrington NM, Freathy RM, Neale MC, Evans DM. Using structural equation
717 modelling to jointly estimate maternal and fetal effects on birthweight in the UK Biobank. Int
718 J Epidemiol. 2018;47(4):1229-41.
719 57. Bond TA, Richmond RC, Karhunen V, Cuellar-Partida G, Borges MC, Zuber V, et al.
720 Exploring the causal effect of maternal pregnancy adiposity on offspring adiposity: Mendelian
721 randomisation using polygenic risk scores. BMC Medicine. 2022;20(1):34.
722 58. Wu Y, Zhong X, Lin Y, Zhao Z, Chen J, Zheng B, et al. Estimating genetic nurture with
723 summary statistics of multigenerational genome-wide association studies. Proc Natl Acad Sci
724 U S A. 2021;118(25).
725 59. Beaumont RN, Flatley C, Vaudel M, Wu X, Chen J, Moen GH, et al. Genome-wide
726 association study of placental weight identifies distinct and shared genetic influences
727 between placental and fetal growth. Nat Genet. 2023;55(11):1807-19.
728 60. Warrington NM, Hwang L-D, Nivard MG, Evans DM. Estimating direct and indirect
729 genetic effects on offspring phenotypes using genome-wide summary results data. Nature
730 Communications. 2021;12(1):5420.
731 61. Jiang L, Zheng Z, Qi T, Kemper KE, Wray NR, Visscher PM, et al. A resource-efficient
732 tool for mixed model association analysis of large-scale data. Nat Genet. 2019;51(12):1749-
733 55.
734 62. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide
735 association scans. Bioinformatics. 2010;26(17):2190-1.
736 63. Burgess S, & Thompson, S.G. Mendelian Randomization: Methods for Causal
737 Inference Using Genetic Variants. 2nd edition ed: Chapman and Hall/CRC. ; 2021.
738 64. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
739 instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol.
740 2015;44(2):512-25.
741 65. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
742 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet
743 Epidemiol. 2016;40(4):304-14.

66. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985-98.
67. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377-89.
68. Taylor AE, Morris RW, Fluharty ME, Bjorngaard JH, Åsvold BO, Gabrielsen ME, et al. Stratification by Smoking Status Reveals an Association of CHRNA5-A3-B4 Genotype with Body Mass Index in Never Smokers. PLOS Genetics. 2014;10(12):e1004799.
69. Carreras-Torres R, Johansson M, Haycock PC, Relton CL, Davey Smith G, Brennan P, et al. Role of obesity in smoking behaviour: Mendelian randomisation study in UK Biobank. Bmj. 2018;361:k1767.
70. Khouja JN, Wootton RE, Taylor AE, Davey Smith G, Munafò MR. Association of genetic liability to smoking initiation with e-cigarette use in young adults: A cohort study. PLoS Med. 2021;18(3):e1003555.
71. Schellhas L, Haan E, Easey KE, Wootton RE, Sallis HM, Sharp GC, et al. Maternal and child genetic liability for smoking and caffeine consumption and child mental health: an intergenerational genetic risk score analysis in the ALSPAC cohort. Addiction. 2021;116(11):3153-66.
72. Sanderson E, Richardson TG, Morris TT, Tilling K, Davey Smith G. Estimation of causal effects of a time-varying exposure at multiple time points through multivariable mendelian randomization. PLoS Genet. 2022;18(7):e1010290.
73. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;181(4):251-60.
74. Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34(5):502-8.
75. Brito Nunes C, Huang P, Wang G, Lundberg M, D'Urso S, Wootton RE, et al. Mendelian randomization study of maternal coffee consumption and its influence on birthweight, stillbirth, miscarriage, gestational age and pre-term birth. Int J Epidemiol. 2023;52(1):165-77.
76. Wang G, Bhatta L, Moen GH, Hwang LD, Kemp JP, Bond TA, et al. Investigating a Potential Causal Relationship Between Maternal Blood Pressure During Pregnancy and Future Offspring Cardiometabolic Health. Hypertension. 2022;79(1):170-7.
77. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet. 2011;88(1):76-82.
78. Support ST. StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC. 2019 [
79. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291-5.
80. Bond TB, L; Yang, Q; Moen, Gunn-H; Wang, G; Beaumont, RN; Morris, T; Hwang, L-D; Wootton, RE; Corfield, EC; Warrington, NM; Magnus, MC; Havdhal, A; Borges, MC; Lawlor, DA; Åsvold, B-O; Brumpton, BM; Evans, DM. Parental body mass index and offspring cardiovascular risk factors in adulthood: an intergenerational Mendelian randomization study. In preparation. 2024.
81. L B, TA B, NM W, G W, DM E, Lawlor D, et al. Leveraging parental genotypes to understand the effect of maternal glycemia on offspring cardiometabolic factors in adulthood: an intergenerational Genome-Wide Association and Mendelian randomization Study. In preparation. 2024.

82. Gao YJ, Holloway AC, Su LY, Takemori K, Lu C, Lee RM. Effects of fetal and neonatal exposure to nicotine on blood pressure and perivascular adipose tissue function in adult life. Eur J Pharmacol. 2008;590(1-3):264-8.
83. Somm E, Schwitzgebel VM, Vauthay DM, Aubert ML, Hüppi PS. Prenatal nicotine exposure and the programming of metabolic and cardiovascular disorders. Mol Cell Endocrinol. 2009;304(1-2):69-77.
84. Parsons TJ, Power C, Manor O. Fetal and early life growth and body mass index from birth to early adulthood in 1958 British cohort: longitudinal study. Bmj. 2001;323(7325):1331-5.
85. Simmons R. Perinatal programming of obesity. Semin Perinatol. 2008;32(5):371-4.
86. Howe LD, Matijasevich A, Tilling K, Brion M-J, Leary SD, Smith GD, et al. Maternal smoking during pregnancy and offspring trajectories of height and adiposity: comparing maternal and paternal associations. International Journal of Epidemiology. 2012;41(3):722-32.
87. Brumpton B, Sanderson E, Heilbron K, Hartwig FP, Harrison S, Vie GÅ, et al. Avoiding dynastic, assortative mating, and population stratification biases in Mendelian randomization through within-family analyses. Nature Communications. 2020;11(1):3519.
88. da Silva Magalhães EI, Peixoto Lima N, Baptista Menezes AM, Gonçalves H, Wehrmeister FC, Formoso Assunção M, et al. Maternal smoking during pregnancy and offspring body composition in adulthood: Results from two birth cohort studies. BMJ Open. 2019;9(6):e023852.
89. Hartwig FP, Davies NM, Davey Smith G. Bias in Mendelian randomization due to assortative mating. Genet Epidemiol. 2018;42(7):608-20.
90. Wu Y, Zhong X, Lin Y, Zhao Z, Chen J, Zheng B, et al. Estimating genetic nurture with summary statistics of multigenerational genome-wide association studies. Proceedings of the National Academy of Sciences. 2021;118(25):e2023184118.
91. Beaumont RN, Flatley C, Vaudel M, Wu X, Chen J, Moen G-H, et al. Genome-wide association study of placental weight in 179,025 children and parents reveals distinct and shared genetic influences between placental and fetal growth. medRxiv. 2022:2022.11.25.22282723.
92. Lawlor D, Richmond R, Warrington N, McMahon G, Davey Smith G, Bowden J, et al. Using Mendelian randomization to determine causal effects of maternal pregnancy (intrauterine) exposures on offspring outcomes: Sources of bias and methods for assessing them. Wellcome Open Res. 2017;2:11.
93. Reed ZE, Wootton RE, Khouja JN, Richardson TG, Sanderson E, Davey Smith G, et al. Exploring pleiotropy in Mendelian randomisation analyses: What are genetic variants associated with “cigarette smoking initiation” really capturing? medRxiv. 2023:2023.08.04.23293638.
94. Gage SH, Sallis HM, Lassi G, Wootton RE, Mokrysz C, Davey Smith G, et al. Does smoking cause lower educational attainment and general cognitive ability? Triangulation of causal evidence using multiple study designs. Psychol Med. 2022;52(8):1578-86.
95. Thorgeirsson TE, Gudbjartsson DF, Sulem P, Besenbacher S, Styrkarsdottir U, Thorleifsson G, et al. A common biological basis of obesity and nicotine addiction. Transl Psychiatry. 2013;3(10):e308.
96. Winkler TW, Justice AE, Graff M, Barata L, Feitosa MF, Chu S, et al. The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genet. 2015;11(10):e1005378.

838

Sources of funding.

The genotyping in HUNT was financed by the National Institutes of Health (NIH); University of Michigan; The Research Council of Norway; The Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St. Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU. This work was in part supported by the Integrative Epidemiology Unit which receives funding from the UK Medical Research Council and the University of Bristol (MC_UU_00032/01 and MC_UU_00032/05). The UK Medical Research Council and Wellcome (Grant ref: MR/Z505924/1) and the University of Bristol provide core support for ALSPAC. Genotyping of the ALSPAC maternal samples was funded by the Wellcome Trust (WT088806) and the offspring samples were genotyped by Sample Logistics and Genotyping Facilities at the Wellcome Trust Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); this research was specifically funded by Wellcome Trust and MRC (076467/Z/05/Z, 102215/2/13/2) and British Heart Foundation (BHF) (CS/15/6/31468). This publication is the work of the authors and will serve as guarantors for the contents of this paper. GDS conducts research at the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. GMP was supported by the GW4 Biomed Doctoral Training Programme, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI (MR/N0137941/1) whilst completing this work. GW and NMW are supported by a National Health and Medical Research Council (NHMRC; Australia) Emerging Leadership Fellowship (APP2008723). DME is funded by an Australian National Health and Medical Research Council Investigator Grant (APP2017942). GHM is the recipient of an Australian Research Council Discovery Early Career Award (Project number: DE220101226) funded by the Australian Government and supported by the Research Council of Norway (Project grant: 325640 & Mobility grant: 287198). DAL's contribution is supported by the British Heart Foundation (CH/F/20/90003 & AA/18/1/34219) and European Research Council (grant No. 101021566). DAL's contribution to this work is supported by the European Research

council (101021566) and BHF (CH/F/20/90003 and AA/18/1/34219), and TAB's work was supported by the BHF (AA/18/1/34219). LB, BOA, and BMB work in a research unit funded by the Liaison Committee for education, research and innovation in Central Norway and the Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU.

Data and code sharing.

Data access for the Avon Longitudinal Study of Parents and Children (ALSPAC) operates via a managed open access system. Approved proposals are reviewed by the ALSPAC Executive Committee. Full details are provided in the ALSPAC Data Management Plan (www.bristol.ac.uk/alspac/researchers/data-access/documents/alspac-data-management-plan.pdf). To request access to data from the Trøndelag Health Study (HUNT), researchers affiliated with Norwegian research institutes can apply for the use of HUNT data and biological samples, subject to approval by the Regional Committee for Medical and Health Research Ethics. Researchers from other countries may also apply if collaborating with a Norwegian Principal Investigator. All applications are reviewed by the HUNT Data Access Committee, and successful applicants are required to enter into data access and/or material transfer agreements. Detailed information on the application process, ethical requirements, and available datasets can be found on the HUNT website (www.ntnu.edu/hunt/data). Access to UK Biobank (UKB) data is obtained through a standard application process. Researchers register with UKB, submit a study proposal, and obtain approval from the UKB Access Management Team. Approved applicants receive access to de-identified data under UKB's terms of use. Further information is available on the UK Biobank website (www.ukbiobank.ac.uk/enable-your-research/apply-for-access).

Upon publication, analysis code used in this study will be made publicly available via GitHub repository.

None of the material has been published or is under consideration for publication elsewhere.

Competing interests.

All authors declare no competing interests.

898 FIGURES.

899 Figure 1. Study design overview and flowchart for instruments used in two-sample MR
900 (GWAS).

901 Figure 2. Directed acyclic graphs indicating two scenarios to explain the causal effect of
902 parental smoking on offspring cardiometabolic risk factors in adulthood. A. Intergenerational
903 MR estimating maternal smoking on offspring cardiometabolic risk factors in adulthood. The
904 offspring and paternal SNP are adjusted for, and thus dotted paths are blocked B.
905 Intergenerational MR estimating paternal smoking on offspring cardiometabolic risk factors in
906 adulthood. The offspring and maternal SNP are adjusted for, and thus dotted paths are
907 blocked.

908 Figure 3. Two-sample MR for maternal and paternal smoking heaviness and initiation onto 11
909 long term cardiometabolic outcomes in offspring. A. Maternal smoking on offspring
910 cardiometabolic risk factors in adulthood. B. Paternal smoking on offspring cardiometabolic
911 risk factors in adulthood. MR estimates for the effect of smoking heaviness can be interpreted
912 as the average change in the outcome, in standard deviation (SD) units, per one SD greater
913 parental cigarettes smoked per day. MR estimates for the effect of smoking initiation can be
914 interpreted as the average change in the outcome, in SD units, per doubling in the odds of
915 smoking initiation.

916 Figure 4. One-sample MR for smoking heaviness onto 9 long term cardiometabolic outcomes
917 in offspring. A. Maternal smoking on offspring cardiometabolic risk factors in adulthood. B.
918 Paternal smoking on offspring cardiometabolic risk factors in adulthood. Estimates represent
919 the average change in offspring cardiometabolic outcomes per additional effect allele in the
920 unweighted smoking GRS and per copy of the CHRNA5 risk allele, expressed in standard
921 deviation (SD) units of each outcome. These estimates reflect associations between the
922 parental genetic instruments and offspring outcomes, rather than causal effects per unit
923 change in smoking heaviness.

924 Figure 5. Two-sample MR for maternal and paternal smoking heaviness and initiation onto
925 birthweight in offspring, stratified by parental smoking status, using unadjusted (marginal)
926 genetic effects. A. Maternal smoking exposures on birthweight. B. Paternal smoking exposures
927 on birthweight. MR estimates for the effect of smoking heaviness can be interpreted as the

928 average change in the outcome, in standard deviation (SD) units, per one SD greater parental
929 cigarettes smoked per day. MR estimates for the effect of smoking initiation can be interpreted
930 as the average change in the outcome, in SD units, per doubling in the odds of smoking
931 initiation.

932 Figure 6. One-sample MR for maternal smoking heaviness onto 9 long term cardiometabolic
933 outcomes in offspring in maternal ever and never smokers. A. Maternal smoking on offspring
934 cardiometabolic risk factors in adulthood in maternal ever smoking group. B. Maternal smoking
935 on offspring cardiometabolic risk factors in adulthood in maternal never smokers. Estimates
936 represent the average change in offspring cardiometabolic outcomes per additional effect
937 allele in the unweighted smoking GRS and per copy of the CHRNA5 risk allele, expressed in
938 standard deviation (SD) units of each outcome. These estimates reflect associations between
939 the parental genetic instruments and offspring outcomes, rather than causal effects per unit
940 change in smoking heaviness.

941 TABLES.

942 Table 1. Descriptive statistics of the offspring's cardiometabolic traits for mother-father-
943 offspring trios in HUNT, UKB and ALSPAC.



Figure 1. Study design overview and flowchart for instruments used in two-sample MR (GWAS) (Figure adapted from Bond, T and Bhatta, L 2025 (41, 42)).

BMI: body mass index, BW: birth weight, HUNT: Trøndelag Health Study, UKB: UK Biobank, ALSPAC: Avon Longitudinal Study of Parents and Children, EGG: Early Growth Genetics Consortium, GIANT: Genetic Investigation of Anthropometric Traits Consortium, GWAS: genome-wide association study, QC: quality control, MAF: minor allele frequency. BW: birth weight, HUNT: Trøndelag Health Study, UKB: UK Biobank, ALSPAC: Avon Longitudinal Study of Parents and Children, EGG: Early Growth Genetics Consortium, GIANT: Genetic Investigation of Anthropometric Traits Consortium, GWAS: genome wide association study, QC: quality control, MAF: minor allele frequency. a: total number of participants in the HUNT2 and HUNT3 study waves, b: total number of fetuses included in ALSPAC (including participants recruited after 7 years of age), c: only unrelated individuals within the parent and offspring generations were included in the designated samples, d: sample sizes were similar for the other adult outcomes, e: ALSPAC data were included in EGG, f: in HUNT, the parent-offspring samples included siblings in the offspring generation, and for the birth weight analyses parent-offspring pairs were identified via a birth registry instead of via genetic data, resulting in larger samples for parental GWAS and a smaller sample for offspring GWAS compared with adult outcomes, g: we used publicly available summary statistics from the meta-analysis of EGG, UKB and deCODE carried out by Juliusdottir *et al*. (30), h: prior to meta-analysis, A/T and C/G SNPs were removed when comparison of their allele frequency to the HRC or 1000 Genome Project reference panel suggested harmonisation errors.



Figure 2. Directed acyclic graphs indicating two scenarios to explain the causal effect of parental smoking on offspring cardiometabolic risk factors in adulthood. A. Intergenerational MR estimating maternal smoking on offspring cardiometabolic risk factors in adulthood. The offspring and paternal SNP are adjusted for and thus dotted paths are blocked B. Intergenerational MR estimating paternal smoking on offspring cardiometabolic risk factors in adulthood. The offspring and maternal SNP are adjusted for and thus dotted paths are blocked.



Figure 3. Two-sample MR for maternal and paternal smoking heaviness and initiation onto 11 long term cardiometabolic outcomes in offspring. Parental genotype was adjusted for offspring genotype (duos WLM). A. Maternal smoking on offspring cardiometabolic risk factors in adulthood. B. Paternal smoking on offspring cardiometabolic risk factors in adulthood. MR estimates for the effect of smoking heaviness can be interpreted as the average change in the outcome, in standard deviation (SD) units, per one SD greater parental cigarettes smoked per day. MR estimates for the effect of smoking initiation can be interpreted as the average change in the outcome, in SD units, per doubling in the odds of smoking initiation.



Figure 4. One-sample MR for smoking heaviness onto 9 long term cardiometabolic outcomes in offspring. A. Maternal smoking on offspring cardiometabolic risk factors in adulthood. B. Paternal smoking on offspring cardiometabolic risk factors in adulthood. Estimates represent the average change in offspring cardiometabolic outcomes per additional effect allele in the unweighted smoking GRS and per copy of the CHRNA5 risk allele, expressed in standard deviation (SD) units of each outcome. These estimates reflect associations between the parental genetic instruments and offspring outcomes, rather than causal effects per unit change in smoking heaviness.



Figure 5. Two-sample MR for maternal and paternal smoking heaviness and initiation onto birthweight in offspring, stratified by parental smoking status, using unadjusted (marginal) genetic effects. A. Maternal smoking exposures on birthweight. B. Paternal smoking exposures on birthweight. MR estimates for the effect of smoking heaviness can be interpreted as the average change in the outcome, in standard deviation (SD) units, per one SD greater parental cigarettes smoked per day. MR estimates for the effect of smoking initiation can be interpreted as the average change in the outcome, in SD units, per doubling in the odds of smoking initiation.



Figure 6. One-sample MR for maternal smoking heaviness onto 9 long term cardiometabolic outcomes in offspring in maternal ever and never smokers. A. Maternal smoking on offspring cardiometabolic risk factors in adulthood in maternal ever smoking group. B. Maternal smoking on offspring cardiometabolic risk factors in adulthood in maternal never smokers. Estimates represent the average change in offspring cardiometabolic outcomes per additional effect allele in the unweighted smoking GRS and per copy of the CHRNA5 risk allele, expressed in standard deviation (SD) units of each outcome. These estimates reflect associations between the parental genetic instruments and offspring outcomes, rather than causal effects per unit change in smoking heaviness.

1033 Table 1. Descriptive statistics of the offspring's cardiometabolic traits for mother-father-
1034 offspring trios in HUNT, UKB and ALSPAC.

Offspring Trait (Unit)	HUNT			UKB			ALSPAC		
	Mother-father-offspring trios			Mother-father-offspring trios			Mother-father-offspring trios		
	N	Mean (SD)	Median (Min-Max)	N	Mean (SD)	Median (Min-Max)	N	Mean (SD)	Median (Min-Max)
BMI (kg/m^2)	15731	26.30 (4.36)	25.7 (15.8-50.3)	993	26.44 (4.65)	25.90 (17.58-46.75)	749	24.43 (4.40)	23.50 (16.27-44.59)
WHR	15634	0.87 (0.08)	0.87 (0.58-1.31)	997	0.84 (0.09)	0.84 (0.59-1.08)	748	0.80 (0.07)	0.80 (0.65-1.04)
SBP (mmHg)	15721	125.90 (15.69)	124.00 (70.00-218.00)	997	127.34 (15.05)	125.50 (91.50-183.00)	756	116.92 (12.23)	116.33 (88.67-164.67)
DBP (mmHg)	15721	72.17 (11.27)	71.00 (38.00-126.00)	997	79.93 (10.46)	79.00 (52.00-118.50)	756	66.62 (7.98)	66.00 (42.33-95.00)
Glucose (mmol/L)	15427	5.18 (0.94)	5.00 (2.30-12.60)	866	4.82 (0.65)	4.79 (2.84-10.33)	649	5.27 (0.48)	5.23 (4.03-6.85)
TC (mmol/L)	15481	5.17 (1.05)	5.10 (2.10-10.90)	955	5.44 (1.01)	5.36 (3.22-8.70)	650	4.42 (0.83)	4.32 (2.02-7.33)
HDL-C (mmol/L)	15474	1.32 (0.33)	1.30 (0.50-2.80)	866	1.39 (0.33)	1.36 (0.65-3.16)	650	1.58 (0.43)	1.53 (0.45-3.18)
LDL-C (mmol/L)	15459	3.54 (0.98)	3.44 (0.76-9.38)	955	3.41 (0.80)	3.31 (1.42-6.02)	649	2.40 (0.77)	2.34 (0.15-5.75)
TG (mmol/L)	15702	1.52 (0.99)	1.28 (0.18-11.73)	950	1.58 (1.03)	1.28 (0.39-6.13)	643	0.95 (0.44)	0.82 (0.27-3.41)
CRP† (mg/L)	NA	NA	NA	948	1.82 (2.45)	0.99 (0.09-21.81)	607	1.68 (2.66)	0.72 (0.10-27.69)
HbA1c (mmol/mol)	NA	NA	NA	960	33.36 (3.97)	33.30 (18.10-58.20)	NA	NA	NA

1035
1036 † Traits have been natural log-transformed in one-sample GRS analyses but descriptive statistics presented in the
1037 table are on the original scales; DBP: Diastolic blood pressure; SBP: Systolic blood pressure; BMI: Body mass index;
1038 TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C High-density lipoprotein cholesterol; TG:
1039 Triglycerides; HbA1c: Glycated haemoglobin; CRP: C-reactive protein; WHR: Waist-hip-ratio; N: number of
1040 offspring with the trait measured; SD: standard deviation; Min: minimum measurement; Max: maximum
1041 measurement.

1042